menu search

Psyched wellness announces key findings from 90-day oral toxicity study on amanita muscaria extract

Psyched Wellness (CSE:PSYC, OTCQB:PSYCF) Ltd said KGK, a contract research organisation, has reported key recent findings from the analysis of intest...

April 26, 2022, 8:52 am

Here is why nkarta is 40% up

Nkarta Inc. (NASDAQ: NKTX) is up 40% after announcing positive preliminary Phase 1 findings from its dose-finding trials of NKX101 and NKX019 in hemat...

April 25, 2022, 12:51 pm

Why nkarta stock is soaring today

Nkarta Inc (NASDAQ: NKTX) shares are trading higher Monday morning after the company announced positive preliminary Phase 1 data from independent dos...

April 25, 2022, 9:06 am

Context therapeutics reveals “encouraging” preclinical data from two cancer-treating pipeline programs

Context Therapeutics (NASDAQ:CNTX) Inc announced what it called “encouraging” preclinical data from two pipeline programs, including in vivo co...

April 11, 2022, 10:27 am

Gracell biotechnologies to present data at aacr annual meeting 2022 showcasing early first-in-human results for gc502 in r/r b-all

Allogeneic, off-the-shelf CAR-T therapy with CD19/CD7 dual-directed CAR shows promising early results in patients with r/r B-ALL PALO ALTO, Calif. and...

April 8, 2022, 4:00 pm

Why icosavax's shares are trading lower today

Icosavax Inc (NASDAQ: ICVX) has announced topline interim results from its ongoing Phase 1/2 trial of IVX-411, a VLP vaccine candidate displaying t...

March 25, 2022, 9:16 am

Anavex's blarcamesine and cassava sciences' simufilam: the stabilization period for alzheimer's disease

Aricept and blarcamesine limit further oxidative stress in Alzheimer's disease via agonism of Sigma-1 receptor...

March 22, 2022, 10:16 pm

Why are immunogen shares trading lower today

ImmunoGen Inc (NASDAQ: IMGN) shared full results from the SORAYA trial evaluating mirvetuximab in folate re...

March 21, 2022, 8:28 am

Celyad oncology to announce full year 2021 financial results and host conference call

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--Regulatory News: Celyad Oncology SA (Euronext & Nasdaq: CYAD) (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD)...

March 17, 2022, 2:01 am

Theseus pharmaceuticals to present preclinical data characterizing next-generation epidermal growth factor receptor (egfr) inhibitors at the 2022 american association for cancer research (aacr) annual

CAMBRIDGE, Mass., March 8, 2022 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceut...

March 8, 2022, 5:01 pm

Theseus pharmaceuticals to present preclinical data characterizing next-generation epidermal growth factor receptor (egfr) inhibitors at the 2022 american association for cancer research (aacr) annual

CAMBRIDGE, Mass., March 8, 2022 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceut...

March 8, 2022, 5:01 pm

Theseus pharmaceuticals to present preclinical data characterizing next-generation epidermal growth factor receptor (egfr) inhibitors at the 2022 american association for cancer research (aacr) annual

CAMBRIDGE, Mass., March 8, 2022 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceut...

March 8, 2022, 5:01 pm

Relmada aces rel-1017 vs ketamine study for abuse potential

Relmada Therapeutics Inc (NASDAQ: RLMD) has announced topline results of the human abuse potential (HAP) study with REL-1017 for major depressive d...

February 23, 2022, 11:42 am

Relmada aces rel-1017 vs ketamine study for abuse potential

Relmada Therapeutics Inc (NASDAQ: RLMD) has announced topline results of the human abuse potential (HAP) study with REL-1017 for major depressive d...

February 23, 2022, 11:42 am

Relmada aces rel-1017 vs ketamine study for abuse potential

Relmada Therapeutics Inc (NASDAQ: RLMD) has announced topline results of the human abuse potential (HAP) study with REL-1017 for major depressive d...

February 23, 2022, 11:42 am

Biontech, medigene ink immunotherapy pact against cancer

BioNTech SE (NASDAQ: BNTX) and Medigene AG have entered a multi-target research collaboration to develop T cell ...

February 22, 2022, 7:31 am

Biontech, medigene ink immunotherapy pact against cancer

BioNTech SE (NASDAQ: BNTX) and Medigene AG have entered a multi-target research collaboration to develop T cell ...

February 22, 2022, 7:31 am

Biontech, medigene ink immunotherapy pact against cancer

BioNTech SE (NASDAQ: BNTX) and Medigene AG have entered a multi-target research collaboration to develop T cell ...

February 22, 2022, 7:31 am

Biovaxys says studies on bvx-0320, its haptenized sars-cov-2 s-spike protein vaccine, suggest superior cardiac safety

BioVaxys Technology Corp has revealed that studies on BVX-0320, its haptenized SARS-CoV-2 s-spike protein vaccine candidate, demonstrated that the va...

February 16, 2022, 9:48 am

Biovaxys says studies on bvx-0320, its haptenized sars-cov-2 s-spike protein vaccine, suggest superior cardiac safety

BioVaxys Technology Corp has revealed that studies on BVX-0320, its haptenized SARS-CoV-2 s-spike protein vaccine candidate, demonstrated that the va...

February 16, 2022, 9:48 am


Search within

Pages Search Results: